-+ 0.00%
-+ 0.00%
-+ 0.00%

TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm

Benzinga·12/07/2025 22:49:58
Listen to the news

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced updated results from the ongoing ALLOHA™ Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). The data is being featured in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc. on Monday, December 8, at 8:00 a.m. ET

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52)

3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control arm

TSC-101 was well-tolerated with no dose-limiting toxicities observed